<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663308</url>
  </required_header>
  <id_info>
    <org_study_id>VLX-301</org_study_id>
    <secondary_id>2020-003027-41</secondary_id>
    <nct_id>NCT04663308</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)</brief_title>
  <acronym>VISTAS</acronym>
  <official_title>A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn more about the use of the study&#xD;
      medicine, volixibat, for the treatment of pruritus (itching) associated with Primary&#xD;
      Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of&#xD;
      PSC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the daily itch scores using the Adult Itch Reported Outcome (Adult ItchRO) questionnaire</measure>
    <time_frame>Baseline through to Week 28</time_frame>
    <description>The Adult ItchRO is an 11-point NRS measurement of itch severity ranging from 0=no itch to 10=worst possible itch.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with itch response using the Adult ItchRO</measure>
    <time_frame>Baseline through to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events</measure>
    <time_frame>Baseline through to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting serum bile acid levels</measure>
    <time_frame>Baseline through to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in alanine transaminase</measure>
    <time_frame>Baseline through to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in aspartate transaminase</measure>
    <time_frame>Baseline through to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in alkaline phosphatase</measure>
    <time_frame>Baseline through to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bilirubin levels</measure>
    <time_frame>Baseline through to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Primary Sclerosing Cholangitis-Specific Patient-Reported Outcome</measure>
    <time_frame>Baseline through to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) fatigue questionnaire</measure>
    <time_frame>Baseline through to Week 28</time_frame>
    <description>The PROMIS® Fatigue questionnaire is a 5-point response scale. Respondents endorse each item using a 5-point response scale: Never, Rarely, Sometimes, Often, and Always.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) sleep disturbance questionnaire</measure>
    <time_frame>Baseline through to Week 28</time_frame>
    <description>The PROMIS® Sleep Disturbance in an 8-item measure that assesses quality of sleep, sleep depth, and restoration associated with sleep. It is a 5-point response scale, the specific response options vary by items. The first 4 items use response options that range from Not at all to Very much. The next 3 items use response options that range from Never to Always. The final item assesses sleep quality ranging from Very poor to Very good.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Volixibat 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive volixibat 20mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volixibat 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive volixibat 80mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volixibat</intervention_name>
    <description>Oral capsules, administered twice daily. Volixibat is an apical sodium-dependent bile acid transporter (ASBT) inhibitor.</description>
    <arm_group_label>Volixibat 20mg</arm_group_label>
    <arm_group_label>Volixibat 80mg</arm_group_label>
    <other_name>SHP626</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules matched to study drug minus active substance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide freely signed informed consent and be willing to comply with all study visits&#xD;
             and requirements through end of study, including the follow-up period.&#xD;
&#xD;
          2. Subjects aged ≥18 years.&#xD;
&#xD;
          3. Confirmed diagnosis of large duct or small duct PSC based on American Association for&#xD;
             the Study of Liver Disease (AASLD) guidelines.&#xD;
&#xD;
          4. Qualified pruritus associated with PSC as assessed by Adult ItchRO.&#xD;
&#xD;
          5. Ursodeoxycholic acid (UDCA) and anti-pruritic medication use will be allowed if&#xD;
             meeting additional criteria.&#xD;
&#xD;
          6. Concomitant Inflammatory Bowel Disease (IBD) is allowed if meeting additional&#xD;
             criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pruritus associated with an etiology other than PSC&#xD;
&#xD;
          2. Evidence or clinical suspicion of decompensated cirrhosis, or a history of&#xD;
             decompensation events&#xD;
&#xD;
          3. History of ileostomy or small bowel surgery/resection or other surgeries that may have&#xD;
             disrupted the enterohepatic circulation&#xD;
&#xD;
          4. Evidence, history, or suspicion of other liver diseases&#xD;
&#xD;
          5. Bile duct stent or percutaneous bile duct drain placement, or balloon dilatation&#xD;
             procedure of a stricture within 12 weeks of Screening&#xD;
&#xD;
          6. Exceeding pre-defined biochemical values for alanine aminotransferase/aspartate&#xD;
             aminotransferase (ALT/AST), estimated glomerular filtration rate (eGFR),serum&#xD;
             creatinine (sCr), platelet count, international normalized ratio (INR) and total&#xD;
             bilirubin&#xD;
&#xD;
          7. History of liver transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Mirum</last_name>
    <phone>+16506674085</phone>
    <email>clinicaltrials@mirumpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medinfo Mirum</last_name>
    <email>medinfo@mirumpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tarek Hassanein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilia Zograbyan</last_name>
      <phone>310-423-1269</phone>
      <email>Lilia.Zograbyan@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Walid Ayoub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Bowlus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Nguyen</last_name>
      <phone>415-600-5708</phone>
      <email>nguyel18@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kidist Yimam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado - Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aryana Rasti</last_name>
      <phone>303-724-1866</phone>
      <email>aryana.rasti@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Forman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arun Khazanchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami - Schiff Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cynthia Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Shea</last_name>
      <phone>617-632-1129</phone>
      <email>jmshea@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Bonder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stuart Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Lake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Liver and GI Specialists</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brian Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmen Stanca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munazza Zakir-Ullah</last_name>
      <phone>585-276-3798</phone>
      <email>munazza_zakir@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Health - Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julius Wilder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryBeth Luce</last_name>
      <phone>412-647-1461</phone>
      <email>lucem@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Grubich</last_name>
      <phone>412-802-3228</phone>
      <email>grubichhl@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mordechai Rabinovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Porayko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Liver Institute At Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Parvez Mantry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marlyn Mayo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcos De Oliveira</last_name>
      <phone>346-238-0218</phone>
      <email>mdeoliveira@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>David Victor III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Care</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srinivas Mulamalla</last_name>
      <phone>801-585-2283</phone>
      <email>srinivas.mulamalla@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <phone>801-585-2283</phone>
    </contact_backup>
    <investigator>
      <last_name>Juan Gallegos-Orozco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institution of Hampton Roads Mary Immaculate Hospital Office</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mitchell Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richmond Community Hospital LLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mitchell Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington, Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Landis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Institute Northwest</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kris Kowdley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pruritus</keyword>
  <keyword>PSC</keyword>
  <keyword>Itch</keyword>
  <keyword>Itching</keyword>
  <keyword>Cholestasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Volixibat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

